NCT06497010View on ClinicalTrials.gov

An Exploratory Study of Individualized Neo-antigen mRNA Cancer Vaccine InnoPCV in Advanced Solid Tumor Treatment

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

August 29, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions

Advanced Solid Tumor

Interventions

DRUG

Biological: PD-1

Intravenous (IV) infusion

DRUG

Biological: InnoPCV

Intramuscular (IM) injection

Trial Locations (1)

Unknown

RECRUITING

The Affiliated Hospital of Guizhou Medical University, Guiyang

Sponsors

Collaborators (1)

Innovac Therapeutics

All Listed Sponsors

collaborator

Innovac Therapeutics

INDUSTRY

lead

The Affiliated Hospital Of Guizhou Medical University

OTHER